Janumet (metformin sitagliptin): Reviews and patient testimonials
Medication indications
Janumet 50 mg/1000 mg film-coated tablets
For adult patients with type 2 diabetes mellitus:
Janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
Janumet is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
Janumet is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.
Janumet is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
Route of administration: Oral
Molecule: metformin, sitagliptin
Patients' opinions on Janumet
In brief
General satisfaction level: 1.00/10 Learn more
Treatment's effectiveness: 1.00/10 Learn more
Ease of use: 1.00/10 Learn more
Adherence to prescription: 1.00/10 Learn more
Detected side effects: Be the first to evaluate
Improvement in the quality of life: 1.00/10 Learn more
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Never
10 = Always
1 = Not at all important
10 = Extremely important
1 = Not at all satisfied
10 = Extremely satisfied
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.